Scarica l'app Stockscreener
209.23
0.30%
-0.64
Dopo l'orario di chiusura:
211.59
2.36
+1.13%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RVMD Giù?
Forum
Previsione
Precedente Chiudi:
$209.87
Aprire:
$211.36
Volume 24 ore:
1.33M
Relative Volume:
0.53
Capitalizzazione di mercato:
$44.85B
Reddito:
$742.00K
Utile/perdita netta:
$-1.37B
Rapporto P/E:
-29.58
EPS:
-7.0731
Flusso di cassa netto:
$-1.07B
1 W Prestazione:
-2.88%
1M Prestazione:
+11.57%
6M Prestazione:
+105.89%
1 anno Prestazione:
+429.29%
Intervallo 1D:
$205.22
$211.91
Intervallo di 1 settimana:
$200.53
$224.31
Portata 52W:
$38.49
$224.31
Revolution Medicines Inc Stock (RVMD) Company Profile
Nome
Revolution Medicines Inc
Settore
Industria
Telefono
650-481-6801
Indirizzo
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, ARGX, MRNA
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
209.23 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
VRTX
Vertex Pharmaceuticals Inc
|
556.75 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
852.03 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,055.37 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
150.81 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Ripresa | Jefferies | Buy |
| 2026-02-27 | Ripresa | UBS | Buy |
| 2025-11-18 | Iniziato | Wolfe Research | Outperform |
| 2025-11-03 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-10-21 | Iniziato | Mizuho | Outperform |
| 2025-10-16 | Ripresa | Stifel | Buy |
| 2025-09-12 | Ripresa | Raymond James | Strong Buy |
| 2025-09-05 | Iniziato | Truist | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-08-15 | Iniziato | Wells Fargo | Overweight |
| 2025-07-15 | Iniziato | Goldman | Buy |
| 2024-07-16 | Reiterato | Needham | Buy |
| 2024-07-12 | Iniziato | Barclays | Overweight |
| 2024-07-08 | Iniziato | Jefferies | Buy |
| 2024-04-12 | Reiterato | Needham | Buy |
| 2024-04-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | Iniziato | Piper Sandler | Overweight |
| 2024-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-01-04 | Iniziato | Wedbush | Outperform |
| 2023-11-16 | Iniziato | Raymond James | Outperform |
| 2023-02-28 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-10-21 | Iniziato | Oppenheimer | Outperform |
| 2022-05-20 | Iniziato | BofA Securities | Neutral |
| 2022-03-01 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-23 | Iniziato | Stifel | Hold |
| 2021-08-12 | Downgrade | Goldman | Buy → Neutral |
| 2021-05-18 | Iniziato | Goldman | Buy |
| 2020-05-21 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-09 | Iniziato | Cowen | Outperform |
| 2020-03-09 | Iniziato | Guggenheim | Buy |
| 2020-03-09 | Iniziato | JP Morgan | Neutral |
Mostra tutto
Revolution Medicines Inc Borsa (RVMD) Ultime notizie
Revolution Medicines nears lease for 700,000-square-foot Redwood City campus - The Business Journals
Revolution Medicines (NASDAQ: RVMD) trust plans 3,000-share Rule 144 sale - Stock Titan
Revolution Medicines (NASDAQ: RVMD) director plans August stock sale after June $1.6M trade - Stock Titan
Revolution Medicines (NASDAQ: RVMD) holder eyes $16M stock sale - Stock Titan
RVMD Maintained by Bernstein -- Price Target Raised to $179 - GuruFocus
REVOLUTION MEDICINES, INC. : BERNSTEIN RAISES TARGET PRICE TO $179 FROM $151 - Bitget
Price to sales forward of Revolution Medicines, Inc. – NASDAQ:RVMDW - TradingView
Enterprise value to revenue forward of Revolution Medicines, Inc. – NASDAQ:RVMDW - TradingView
Why Revolution Medicines May Be Big Pharma’s Next Takeover Target - AOL.com
Price to book forward of Revolution Medicines, Inc. – NASDAQ:RVMDW - TradingView
Revolution (RVMDW) Price and Levels: Advances 4.09% to $12.59 in Latest Trading; Technical Focus: the $11.96 to $13.22 Range Remains in Focus in the Available RecordBollinger Walk - Vinanet
Why Revolution Medicines (RVMD) Stock Is Up Today - Quiver Quantitative
Revolution Medicines stock hits all-time high at 208.77 USD - Investing.com
Revolution Medicines stock hits all-time high at 208.77 USD By Investing.com - Investing.com Australia
Corcept, Revolution Medicines lead ten large-cap healthcare stocks surging in 2026 (XLV:NYSEARCA) - Seeking Alpha
Revolution Medicines, Inc. (RVMD) Stock Analysis: Exploring Growth Potential with RAS-Targeted Therapies - DirectorsTalk Interviews
State of Wyoming Buys Shares of 9,446 Revolution Medicines, Inc. $RVMD - MarketBeat
S&CO Inc. Invests $6.40 Million in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines (MEX:RVMD) Shiller PE Ratio : (As of Aug. 16, 2026) - GuruFocus
Revolution Medicines Inc Stock Baskets - GuruFocus
Is BeOne Medicines AG (ONC) Deal With Revolution Medicines (RVMD) a Win-Win for Both Companies? - Yahoo Finance
Baker Bros. Advisors (RVMD) discloses 11.4M-share position in Revolution Medicines - Stock Titan
Top Revolution Medicines (RVMDW) Competitors 2026 - MarketBeat
Farallon funds disclose 13.6M-share RVMD stake in Schedule 13G/A filing - Stock Titan
Revolution Medicines (RVMD): Janus Henderson discloses 5.1% beneficial stake - Stock Titan
ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death - Stocktwits
Revolution Medicines (RVMD) Q2 2026 Earnings Call Transcript - AOL.com
(RVMD) Volatility Zones as Tactical Triggers - Stock Traders Daily
Revolution and BeOne Meds enter research pact - thepharmaletter.com
Revolution Medicines hits $44B market cap with breakthrough RAS cancer drugs, attracting big pharma interest. - Pluang
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers - The Manila Times
Revolution Medicines (RVMD) Stock Looks Strong On Returns But Expensive On Value - simplywall.st
Tema ETFs LLC Sells 26,443 Shares of Revolution Medicines, Inc. $RVMD - MarketBeat
Handelsbanken Fonder AB Raises Stock Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines (RVMD) Stock Looks Rich On Fresh RAS Drug Demand - Yahoo Finance
Revolution Medicines (RVMD) Is Up 6.2% After BeOne-Funded Phase 3 RAS(ON) DealHas The Bull Case Changed? - Yahoo Finance
Revolution Medicines (RVMD) Looks Fairly Valued As BeOne Deal Expands Its Asia Reach - Yahoo Finance
Can Revolution Medicines (RVMD) Turn A New Ally Into Global Reach? - Yahoo Finance
BeOne and Revolution Medicines partner for oncology therapies - Pharmaceutical Business review -
BeOne Medicines Enters Collaboration with Revolution Medicines for Oncology Therapies - Pharmaceutical Executive
REVOLUTION MEDICINES, INC. : TRUIST SECURITIES RAISES TARGET PRICE TO $231 FROM $210 - Bitget
Revolution Medicines (NASDAQ:RVMD) Sets New 12-Month HighShould You Buy? - MarketBeat
Bank of America Corp DE Cuts Holdings in Revolution Medicines, Inc. $RVMD - MarketBeat
‘Pharma Bro’ Martin Shkreli Defends Revolution Medicines’ Pancreatic Cancer Study Data: ‘Progress Compounds’ - Stocktwits
Revolution Medicines (RVMD) BeOne Deal Puts Its Valuation Back In Focus - simplywall.st
BeOne and Revolution Medicines partner on RAS(ON) inhibitor combinations in Asia - AllSci
RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 win - Endpoints News
Revolution Medicines stock rating reiterated at Buy by TD Cowen - Investing.com South Africa
BeOne Medicines and Revolution Medicines Partner on RAS(ON) Cancer Therapies - Oncodaily
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration - BioSpace
Revolution Medicines, BeOne Medicines form collaboration on RAS cancer drug combinations - Bitget
Revolution Medicines Inc Azioni (RVMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Revolution Medicines Inc Azioni (RVMD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Cislini Jeff | General Counsel |
Aug 21 '26 |
Sale |
209.24 |
56,894 |
11,904,247 |
55,907 |
| GOLDSMITH MARK A | See Remarks |
Aug 21 '26 |
Option Exercise |
4.73 |
80,000 |
378,400 |
347,330 |
| GOLDSMITH MARK A | See Remarks |
Aug 21 '26 |
Sale |
209.20 |
80,000 |
16,735,887 |
267,330 |
| GOLDSMITH MARK A | See Remarks |
Aug 21 '26 |
Sale |
209.20 |
6,000 |
1,255,219 |
61,424 |
0.87%
2.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):